The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Open accessAbstract
BACKGROUND: Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODS: We enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated LDL cholesterol levels despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned in a 1:1 ratio to receive either inclisiran (284 mg) or placebo, administered by subcutaneous injection on day 1, day 90, and every 6 months thereafter over a period of 540 days. The coprimary end points in each trial were the placebo-corrected percentage change in LDL cholesterol level from baseline to day 510 and the time-adjusted percentage change in LDL cholesterol level from baseline after day 90 and up to day 540. RESULTS: A total of 1561 and 1617 patients underwent randomization in the ORION-10 and ORION-11 trials, respectively. Mean (±SD) LDL cholesterol levels at baseline were 104.7±38.3 mg per deciliter (2.71±0.99 mmol per liter) and 105.5±39.1 mg per deciliter (2.73±1.01 mmol per liter), respectively. At day 510, inclisiran reduced LDL cholesterol levels by 52.3% (95% confidence interval [CI], 48.8 to 55.7) in the ORION-10 trial and by 49.9% (95% CI, 46.6 to 53.1) in the ORION-11 trial, with corresponding time-adjusted reductions of 53.8% (95% CI, 51.3 to 56.2) and 49.2% (95% CI, 46.8 to 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events were generally similar in the inclisiran and placebo groups in each trial, although injection-site adverse events were more frequent with inclisiran than with placebo (2.6% vs. 0.9% in the ORION-10 trial and 4.7% vs. 0.5% in the ORION-11 trial); such reactions were generally mild, and none were severe or persistent. CONCLUSIONS: Reductions in LDL cholesterol levels of approximately 50% were obtained with inclisiran, administered subcutaneously every 6 months. More injection-site adverse events occurred with inclisiran than with placebo. (Funded by the Medicines Company; ORION-10 and ORION-11 ClinicalTrials.gov numbers, NCT03399370 and NCT03400800.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Randomized controlled trials, including the VICTORION-Mono and VICTORION-Difference trials, as well as ORION -10, -11, and other Phase III trials, have consistently demonstrated that inclisiran reduces LDL-C compared with placebo in primary and secondary prevention settings.5, 6, 7”
From Small Interfering RNA for LDL-Cholesterol Reduction (2026) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The trials showed that patients achieved LDL-C decreases of 52.3% and 49.9% at Day 510 [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The ORION-10 and ORION-11 trials achieved LDL-C reductions greater than 50% among their participants [44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The initial injections of inclisiran at Day 1 and 90 followed by biannual maintenance resulted in a long-term average LDL-C reduction of − 44% to − 48% across ORION-1 and ORION-10 and ORION-11 [25, 44].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical observations demonstrate that numerous patients stop taking their daily statin medications or PCSK9 antibody injections irregularly which reduces their ability to prevent cardiovascular diseases [44, 80].”
From Inclisiran SiRNA therapy for durable LDL-C reduction: a systematic review and meta-analysis highlighting a breakthrough in long-term cardiovascular risk management (2026) · cites this paper as [44]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 siRNA and monoclonal antibodies blocking the PCSK9/LDLR interaction potently lower LDL cholesterol and reduce the risk of adverse cardiovascular events (Sabatine et al., 2017; Schwartz et al., 2018; Ray et al., 2020).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, PCSK9 inhibitory antibodies and siRNA potently reduce LDL cholesterol to unprecedented low levels and are approved for treatment of hypercholesterolemia.”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Ray et al., 2020
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“targeted PCSK9 inhibition restores hepatic LDLR levels, decreases plasma LDL-C levels and improves cardiovascular outcomes.7,9–11”
From Sirtuin-1 directly binds and deacetylates hepatic PCSK9 thereby promoting the inhibition of LDL receptor degradation (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The phase 3 ORION-10 and ORION-11 trials evaluated inclisiran compared with placebo across a total of 1561 and 1617 patients with atherosclerosis or an atherosclerotic CVD risk-equivalent, respectively [137]. Compared with placebo, inclisiran reduced LDL-C levels by − 52% and − 50%, respectively.”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [137]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to monoclonal antibodies that sequester PCSK9 in the circulation and are now prescribed to patients, the small-interfering RNA inclisiran that targets PCSK9 hepatic production has recently been approved, following reports of substantial LDL lowering [50% reduction (95% confidence interval 47–53)] with this drug (11).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9, has demonstrated the ability to reduce LDL cholesterol by 49-52% in trials evaluating individuals with established cardiovascular disease or ASCVD risk equivalent (129).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“In addition to the monoclonal antibodies, an siRNA, inclisiran, which also targets PSCK9 and is referred to as a PCSK9 siRNA in this section, has demonstrated the ability to reduce LDL cholesterol by 49–52% in trials evaluating individuals with established CVD or ASCVD risk equivalent (123).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [123]
The cited source says what the claim attributes to it.
In the citing paper
“Inclisiran was noted to decrease LDL by ∼50% in the ORION trials [20]”
From Oral PCSK9 inhibitors for elevated LDL-C: A systematic review and meta-analysis of randomized trials (2026) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“The analysis of 11 RCTs for quantitative synthesis included more than 13,000 participants showed inclisiran produces significant LDL-C reduction versus placebo treatment [24, 25, 38–44, 46, 49].”
The cited source says what the claim attributes to it.
In the citing paper
“Large-scale research including well-powered trials such as ORION 10 and ORION 11 demonstrates that Inclisiran shows strong potential as a potent lipid-lowering agent [44].”
In the citing paper
“Patients on statins with high LDL-C levels and ASCVD or at least one ASCVD risk equivalent were included in the two phase 3 trials ORION-10 and ORION-11 (Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol), and obtained a further 50% reduction of LDL-C with inclisiran.278”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [278]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
Adams, D., Gonzalez-Duarte, A., O’Riordan, W. D., Yang, C.-C., Ueda, M., Kristen, A. V., Tournev, I., Schmidt, H. H., Coelho, T., Berk, J. L., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716153 · Cited by 3,047
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992
Self-citationRodríguez, F., Maron, D. J., Knowles, J. W., Virani, S. S., Lin, S., & Heidenreich, P. A. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4936 · Cited by 347
The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications
Choudhry, N. K., Fischer, M. A., Avorn, J., Liberman, J. N., Schneeweiß, S., Pakes, J., Brennan, T. A., & Shrank, W. H. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.495 · Cited by 314
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,007
Gender differences in the incidence of saphenous vein graft intervention
Osherov, A. B., Gallego-Colón, E., Abu-Alkean, I., Nemik, D. B., Orlov, I., & Jafari, J. (2024) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-024-03139-2 · Cited by 4
Targeting CIDEB alleviates liver steatosis and fibrosis in mouse MASH models
Lin, Y., Fan, F., Mo, Z., Huang, Z., Zhou, M., Ma, Y., Qian, C., Wang, Y., Qian, C., & Liu, X. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102567 · Cited by 4
Daman, K., Yan, J., Biscans, A., Echeverria, D., Shmushkovich, T., Wolfson, A. D., Alterman, J. F., Khvorova, A., & Emerson, C. P. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101513 · Cited by 4
Strategies for the delivery of RNA therapeutics to diseased heart tissue
Nicoletti, L., Coletto, M., Stola, G. P., Paoletti, C., Marcello, E. E., Testore, D., Tivano, F., Zoso, A., Mattu, C., & Chiono, V. (2025) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2025.2539960 · Cited by 5
Walker, M., Riggs, K. A., Rohatgi, A. K., Beckman, J. A., Addo, T. A., Girotra, S. R., Bonaca, M. P., Armstrong, E. J., & Kumbhani, D. J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039734 · Cited by 4
Dysregulated Lipid Metabolism as a Central Driver of Atherosclerotic Plaque Pathology
Steinbeck, J. E., Iannotti, R. A., & Rasheed, A. (2025) · Lipidology · doi:10.3390/lipidology2040017 · Cited by 5
Khattak, S., Ochoa-Ferraro, A. F., Khan, N., George, S., Khan, S. Q., Townend, J., Dawson, C., & Thomas, M. R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227946 · Cited by 4
Ballantyne, C. M., Graham, T. E., Anglen, L. J. V., Iteld, B. J., Serota, H., Niu, X., McElligott, S. C., Hanna, K. E., & Varisco, T. J. (2025) · Cardiology and Therapy · doi:10.1007/s40119-025-00438-0 · Cited by 4
Rossi, R., Nouri, A., Akman, Z., Nezhad, S. A., Damluji, A. A., & Nanna, M. G. (2025) · Current Cardiology Reports · doi:10.1007/s11886-025-02329-1 · Cited by 5
Zhao, M., Liu, W., Lu, W., Li, Z., & Wu, H. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104599 · Cited by 4
Wang, W.-L., Yen, C., Yen, C.-S., Huang, Y.-H., Huang, H.-Y., Chen, J.-F., Liu, Y.-T., Wang, S.-T., Liu, Y., Hung, M., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218255 · Cited by 4
A, A. T., Vallazhath, A., Vijayakumar, M., & Menon, D. (2026) · Journal of Materials Chemistry B · doi:10.1039/d5tb02293b · Cited by 7
Nucleic Acid–Based Therapies — The Next Frontier in Treating Dyslipidemias
Hegele, R. A. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.026 · Cited by 4
Qiu, Z., Wang, R.-Y., Zhang, Y., Huang, H.-B., He, R.-Y., Yan, H., Luo, P., Yang, B., Xu, Z.-F., & He, Q.-J. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01729-x · Cited by 6
Advancing the Landscape of RNAi Nanotherapeutics for Ischemic Heart Disease
Gao, H., Pan, D., & Santos, H. A. (2026) · Advanced Materials · doi:10.1002/adma.202523005 · Cited by 5
SU, H., Guo, X., Li, Q., Yuan, X., Wu, X., Zhao, Z., Kan, Y., Yang, Y., Fu, Z., Qi, Z., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1744830 · Cited by 4
Ballman, K. K., Peek, V. L., Sloan, J. H., Li, J., Konrad, R. J., & Wen, Y. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00914-w · Cited by 4
Kim, Y. J., Malhi, J. K., Trost, J., Leucker, T. M., Virani, S. S., Newby, L. K., Blumenthal, R. S., & Hariri, E. H. (2024) · The American Journal of Medicine · doi:10.1016/j.amjmed.2024.09.013 · Cited by 4
Nucleic Acid Therapy for the Skin
Chai, A. C., Siegwart, D. J., & Wang, R. C. (2024) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2024.07.029 · Cited by 4
Taha, H., Kandil, H., Badran, H. M., Farag, N. M., Khamis, H., Nasr, G. M., Samy, M., Abdrabou, M., Abuelezz, M., & Shaker, M. M. (2024) · The Egyptian Heart Journal · doi:10.1186/s43044-024-00562-7 · Cited by 5
Lipid-lowering agent preferences among patients with hypercholesterolemia: a focus group study
Yiu, H. H. E., Deng, K., Fung, L. W., Ye, X., Blais, J. E., Tse, H., Wong, M. C. S., Yan, B. P., Wong, W. C. W., Li, X., et al. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2421261 · Cited by 5
Zheng, X., Jin, Y., Fan, M., Cui, H., & Zhu, S. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65624 · Cited by 4
Wang, P., Liang, L., & Li, Y. (2025) · Applied Health Economics and Health Policy · doi:10.1007/s40258-025-00971-y · Cited by 4
Orally deliverable biomimetic nucleic acid therapies for targeted treatment of atherosclerosis
Li, C., Chen, Y., Li, Y., Liu, H., Yang, S., Lin, Y., Qi, Y., Han, S., Dou, Y., Luo, G., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.039 · Cited by 5
Huang, Z.-A., Yang, S., Ji, G.-S., Gao, Z.-C., Li, Z.-M., Wang, J., Yu, F., & Song, G.-S. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101609 · Cited by 4
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors
Shaw, P. B. (2021) · The American Journal of Managed Care · doi:10.37765/ajmc.2021.88606 · Cited by 4
CMC and regulatory aspects of oligonucleotide therapeutics
Rupp, T. M., & Cramer, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821595-1.00012-9 · Cited by 4
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date
Rizvi, A. A., Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Almahmeed, W. A., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2094771 · Cited by 4
Genome Editing in Dyslipidemia and Atherosclerosis
Chen, Z., Lehertshuber, C., & Schunkert, H. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-5642-3_10 · Cited by 8
Improving Cardiovascular Risk Assessment to Optimize Therapy
Adolphe, A., Wilder, S., Duro, T., Eaton, R. P., & Schade, D. S. (2023) · World Journal of Cardiovascular Diseases · doi:10.4236/wjcd.2023.131002 · Cited by 4
Updates in the management of pediatric dyslipidemia
Choudhari, P., & Patni, N. (2023) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000879 · Cited by 4
Enea, I., & Martelli, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113652 · Cited by 5
What are the benefits and drawbacks of statins in carotid artery disease? A perspective review
Said, S., Dardik, A., & Chaar, C. I. O. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2286011 · Cited by 5
Ермоленко, В. М. (2024) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2024-28-1-13-29 · Cited by 6
Current and emerging monoclonal antibodies for treating familial hypercholesterolemia in children
Reijman, M. D., Kusters, D. M., & Wiegman, A. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2330948 · Cited by 4
Recent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis
Ariyanto, E. F., Wijaya, I., Pradian, Z. A., Bhaskara, A. P. M., Rahman, P. H. A., & Oktavia, N. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s463221 · Cited by 5
Tsamoulis, D., Rallidis, L. S., & Kosmas, C. E. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2360415 · Cited by 4
Traditional and Novel Markers: Target of Treatment vs Marker of Risk
Mancini, G. B. J., Poirier, P., & Esau, D. (2024) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2024.04.003 · Cited by 4
Clinical Considerations for Healthcare Provider-Administered Lipid-Lowering Medications
Bertolet, B. D., Cabral, K. P., Sullenberger, L. E., McAlister, J., Sandroni, T., & Patel, D. S. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00665-1 · Cited by 4
Movahedan, M., Ellis, U. M., & Barry, A. R. (2024) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-024-00682-0 · Cited by 4
Li, H., Zhao, S., Wu, J., Han, J., Xu, Y., Shi, S., & Zhang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02294-8 · Cited by 5
Chandra, A. A., Espiche, C., Maliha, M., Virani, S. S., Blumenthal, R. S., Rodríguez, F., Wong, N. D., Gulati, M., Slipczuk, L. N., & Shapiro, M. D. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100919 · Cited by 6
Nanoparticle-based siRNA Delivery System in Intestine Empowers the Obesity Management
Yang, J. (2024) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2024.9290110 · Cited by 4
Bettinsoli, V., Melzi, G., Crea, A., Esposti, L. D., Iafisco, M., Catalucci, D., Ciana, P., & Corsini, E. (2025) · Life · doi:10.3390/life15010095 · Cited by 4
Efficacy, benefit and safety of inclisiran
López-Miranda, J. (2024) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2025.100730 · Cited by 4
Evolving concepts of low‐density lipoprotein: From structure to function
Chen, C., Sawamura, T., Akhmedov, A. T., Tsai, M., Akyol, Ö., Kakino, A., Chiang, H., Kraler, S. C., & Lüscher, T. F. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70019 · Cited by 6
Targeting PCSK9 beyond the liver: evidence from experimental and clinical studies
Dalt, L. D., Baragetti, A., & Norata, G. D. (2025) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2025.2482545 · Cited by 4
Vecchia, L. A. D., STEFANO, F. D., Bussotti, M., Godino, C., Bernardi, M., Spadafora, L., Adriano, E. P., Guarini, P., & Pedretti, R. F. E. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06704-3 · Cited by 4
2024 KSoLA Update on New Lipid-Lowering Agents: Inclisiran and Bempedoic Acid
Kim, H., Cha, J., & Lee, S. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.2.135 · Cited by 6
Small interfering RNA (siRNA) in dyslipidemia: a systematic review on safety and efficacy of siRNA
Alla, S. S. M., Shah, D. J., Meyur, S., Agarwal, P., Alla, D., Moraboina, S. L., Ghadvaje, G. V., Bayeh, R. G., Malireddi, A., Shajan, T., et al. (2025) · Journal of Experimental Pharmacology · doi:10.2147/jep.s521579 · Cited by 4
siRNA Interaction and Transfection Properties of Polycationic Phosphorus Dendrimers
Rodríguez-Clemente, I., Karpus, A. O., Buendía, A., Sztandera, K., Regulska, E., Bignon, J. S., Caminade, A., Romero‐Nieto, C., Steinmetz, A. C. U., Mignani, S. M., et al. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c00171 · Cited by 4
Velagapudi, S., Miranda, M. X., Adla, P., Kraler, S., Mohammed, S. A., Baki, S., Robert, J., Rohrer, L., Lee, H., Jang, H.-D., et al. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf087 · Cited by 4
Hubaud, A., & Singh, A. P. (2021) · Trends in Genetics · doi:10.1016/j.tig.2021.04.001 · Cited by 4
Innovative lipid-lowering therapy: experience of inclisiran use in the Republic of Belarus
Medvedeva, E. A., Григоренко, Е. А., & Mitkovskaya, N. P. (2023) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2023-5417 · Cited by 4
Pharmacotherapeutics for dyslipidemia management
Hussein, M. T. E., Sharma, A., Parmar, K., & Shelat, K. (2023) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000059 · Cited by 4
Demidova, T. Y., Izmaylova, M. Y., & Belova, K. M. (2023) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2023-172 · Cited by 4
PCSK9 Targeting in the Management of Hypercholesterolaemia
Kosmas, C. E., Papakonstantinou, E. J., Carreño, J., Uceta, R. E., Guzman, E., & Sourlas, A. (2023) · EMJ Cardiology · doi:10.33590/emjcardiol/10303462 · Cited by 4
Wang, N., Huffman, M. D., Sundström, J., & Rodgers, A. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.08.023 · Cited by 4
An update on emerging drugs for the treatment of hypercholesterolemia
Nelson, A. J., Bubb, K. J., & Nicholls, S. J. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.2009801 · Cited by 4
New and Emerging Therapies for Dyslipidemia
Zambon, A., Averna, M. R., D’Erasmo, L., Arca, M., & Catapano, A. L. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.004 · Cited by 4
Co-repressing immunometabolic processes in atherosclerosis
Stein, S. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2021.02142 · Cited by 4
Michos, E. D., & Ferdinand, K. C. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.9 · Cited by 4
Exceptional Genetics, Generalizable Therapeutics, and Coronary Artery Disease
Natarajan, P. (2024) · New England Journal of Medicine · doi:10.1056/nejme2405647 · Cited by 4
Potent and durable gene modulation in heart and muscle with chemically defined siRNAsPreprint
Fakih, H. H., Lochmann, C., Gagnon, R., Summers, A., Caiazzi, J., Buchwald, J. E., Tang, Q., Maru, B., Hildebrand, S. R., Abideen, M. Z. U., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.01.616183 · Cited by 4
Fan, G., Lu, J., Tan, R., Guo, W., Liang, H., Zha, J., Tang, Z., Yang, J., Yu, Z., & Liu, M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.25.661251 · Cited by 4
Discovery of Truncated Cyclic Peptides Targeting an Induced‐Fit Pocket on PCSK9
Grosche, P., Flyer, A. N., Gattlen, R., Xu, M., Golosov, A. A., Vera, V., Pickett, S., Brousseau, M. E., Chopra, R., Clairmont, K. B., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202400208 · Cited by 3
Using Genomics to Develop Personalized Cardiovascular Treatments
Sanghvi, M. M., Young, W. J., Naderi, H., Burns, R., Ramírez, J., Bell, C. G., & Munroe, P. B. (2025) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.319221 · Cited by 5
Chen, Y., Ke, Y., Jiang, Z., & Yang, G. (2025) · Biomaterials Science · doi:10.1039/d5bm00194c · Cited by 5
Lipoprotein(a) and aortic stenosis: Practical insights
Dimitriadis, K. S., Kyriakoulis, K. G., Pyrpyris, N., Beneki, E., Kamperidis, V., Κόλλιας, Α., Cenko, E., Aznaouridis, K. A., Aggeli, K. D., & Tsioufis, K. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104124 · Cited by 3
Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach
López-Aguilar, E., Pacheco-Velázquez, S. C., Busquets, M.-A., Hay, J., Mueller, P. A., Fazio, S., Ciudad, C. J., Noé, V., & Pamir, N. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116976 · Cited by 3
Ghosh, S., Chaudhury, D., Chowdhury, A., & Jana, N. K. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-96-4959-4_4 · Cited by 3
Grogan, M. A., Sheikh, F. H., Sperry, B. W., Sweetser, M. T., Capocelli, K., Roblin, S., & Witteles, R. M. (2025) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2025.102590 · Cited by 4
Uthman, O. A., Court, R. A., Enderby, J., Nduka, C. U., Al-Khudairy, L., Anjorin, S., Mistry, H., Meléndez‐Torres, G. J., Taylor‐Phillips, S., & Clarke, A. (2024) · Health Technology Assessment · doi:10.3310/rldh7432 · Cited by 4
Choi, J., & Gwon, J. (2025) · Vascular Specialist International · doi:10.5758/vsi.250043 · Cited by 5
Jaiswal, V., Goyal, A., Deb, N., Shama, N., Mittal, V., Rajak, K., Halder, A., Khadka, S., Kumar, T., Ahmed, R., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101311 · Cited by 3
Lupi, A., Baluci, M., Persampieri, S., Perversi, I., Presutti, D. G., Somaschini, A., Gaudio, G. V., Guasti, L., Ferrini, M., Corsini, A., et al. (2025) · Atherosclerosis Plus · doi:10.1016/j.athplu.2025.09.005 · Cited by 3
Lipid lowering therapies in chronic kidney disease: A call to action
Ruiz, J. M., Arroyo, D., de Cos, M., Fernández, M. R., Sánchez-Álvarez, E., Bores, P. G., Hernández, J. L., & Corral, P. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120563 · Cited by 4
Genedy, N., & Zouwail, S. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.008 · Cited by 4
Takahashi, R., Obi, Y., Kalantar-Zadeh, K., & Kovesdy, C. (2025) · Current opinion in nephrology and hypertension · doi:10.1097/mnh.0000000000001131 · Cited by 3
Kaur, S., Panjwani, D., Singh, S., Banerjee, S., Wadehra, S., Kaur, A., & Singh, T. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-025-05459-w · Cited by 3
Interventional genomics: Bridging germline diagnosis and therapeutic action
Giannikopoulos, P., Lauffer, M. C., Marshall, C. R., Costain, G., Niu, Z., Bick, D., Shen, W., Hiemenz, M., Bhatt, S., Grody, W. W., et al. (2026) · Genetics in Medicine · doi:10.1016/j.gim.2026.102532 · Cited by 3
Adjunctive pharmacological strategies for residual risk reduction after myocardial revascularisation
Oshima, A., Serruys, P. W. J. C., Garg, S., McEvoy, J. W., Wood, D. A., Doenst, T., Taggart, D. P., Puskas, J. D., Shajahan, A., Sharif, F., et al. (2026) · EuroIntervention · doi:10.4244/eij-d-25-00598 · Cited by 4
Self-citationKamrul-Hasan, A. B. M., Mahajan, K., Khalil, I., Shahriar, N., Nagendra, L., Dutta, D. J., & Pappachan, J. M. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.02.002 · Cited by 3
Khan, Y., Fatima, R., Ilma, B., Kalra, J. M., Maqbool, M., Ramalingam, P. S., Verma, A., Bansal, N., Ashique, S., & Hussain, M. S. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178676 · Cited by 3
Kafol, J., Fras, Z., Novaković, M., Sperling, L. S., Cevc, M., Krevel, B., Kafol, L., Kelenc, A., Kepic, K., Vrbinc, K. N., et al. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02897-3 · Cited by 3
Luo, Y., Mou, Y., Li, Z., Liao, B. Z. J., & Wan, J. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1793532 · Cited by 3
Genetic factors contributing to atherosclerosis
Raddatz, M. A., Allayee, H., & Lusis, A. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001286 · Cited by 4
mRNA medicine for cardiovascular disease
Zhou, Z., Chen, W., Yu, H., Tabas, I. A., Foo, R., & Tao, W. (2026) · Nature Cardiovascular Research · doi:10.1038/s44161-026-00804-8 · Cited by 6
Knowlton, K. U., Návar, A. M., Anderson, J. L., Brown, A. S., Muhlestein, J. B., Kleeman, K., Sarwat, S., Abbas, C. A., Ramirez, M. A., Grines, C. L., et al. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.043655 · Cited by 3
Catalytic activation of human Argonaute 2 requires RNA duplex deformation
Sarkar, S., Gebert, L. F. R., & MacRae, I. J. (2026) · Nature Structural & Molecular Biology · doi:10.1038/s41594-026-01840-5 · Cited by 3
Review of Lipid-Lowering Therapy in Women from Reproductive to Postmenopausal Years
Witting, C. S., Devareddy, A., & Rodríguez, F. (2022) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2305183 · Cited by 5
Xiang, Y., Xiao, H. T., Muqier, M., Han, S., & Baigude, H. (2022) · RSC Advances · doi:10.1039/d2ra03347j · Cited by 3
Bressy, C., Zemani, A., Goyal, S., Jishkariani, D., Lee, C. N., & Chen, Y. H. (2022) · PLoS ONE · doi:10.1371/journal.pone.0276905 · Cited by 4
Inclisiran in patients with acute ischemic stroke: first data
Cherepianskii, M. S., Ponomareva, G. M., Skiba, I. B., Abakarov, R. M., Дудайте, В. В., & Cherepianskaia, A. A. (2023) · Kardiologiia · doi:10.18087/cardio.2023.10.n2560 · Cited by 3
The Role of Genetics in Advancing Cardiometabolic Drug Development
Abou-Karam, R., Cheng, F., Gady, S., & Fahed, A. C. (2024) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01195-6 · Cited by 3
Rybicka, M., Seroka, A., Obrębski, M., Chwiejczak, J., Górny, A., Kościan, J., Młynarska, J., Szczerkowska, K., Wójcik, A., & Mitkowska, M. (2024) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.212 · Cited by 3
Mining of adverse event signals associated with inclisiran: a post-marketing analysis based on FAERS
Shi, X., Qiao, Y., Yang, Y., Wang, N., Zhang, Y., Shi, S., Shen, G., & Jia, X. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2409707 · Cited by 3
The revolution in pharmacotherapy: from herbs to pills, moulds, antibodies to genetic tools
Lüscher, T. F. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae098 · Cited by 3
Wilson, P. M., Elvey, R., Mathieson, A., Bower, P., Gibson, M., Vell, T., & Dixon, S. (2025) · BMJ Open · doi:10.1136/bmjopen-2023-083441 · Cited by 4
Mak, Y. H., Chua, F., Koh, X. H., Tan, V. H., Lee, Z. H., Lam, A., Tong, K. L., Yeo, C., Chow, W., & Loh, W. J. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2024-172 · Cited by 3
Metadata
- Authors
- Ray, K. K., Wright, R. S., Kallend, D., Koenig, W., Leiter, L. A., Raal, F. J., Bisch, J. A., Richardson, T., Jaros, M., Wijngaard, P. L. J., & Kastelein, J. J. P.
- Affiliations
- Mayo Clinic (US)
- From the Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London (K.K.R.); the Department of Cardiology, Mayo Clinic, Rochester, MN (R.S.W.); the Medicines Company, Zurich, Switzerland (D.K.); Deutsches Herzzentrum München, Technische Universität München, and Deutsches Zentrum für Herz-Kreislauf-Forschung (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, and the Institute of...
- St. Michael's Hospital (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-04-16
- Volume
- 382
- Issue
- 16
- Pages
- 1507-1519
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3012265841
- Semantic Scholar
- 0c86cfdc39f60ff6dc8854a281c1b95f32bdc692
- Cited by
- 1,665
- References
- 19
- Citations by year
- 2026: 296 · 2025: 290 · 2024: 289 · 2023: 273 · 2022: 231 · 2021: 193 · 2020: 87
- FWCI
- 183.81
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- The Medicines Company
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- inclisiran, PCSK9 inhibition, LDL cholesterol lowering, atherosclerotic cardiovascular disease, statin therapy, injection-site adverse events, hypercholesterolemia, lipid-lowering therapy, adverse events, drug safety and efficacy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Aged, Aged, 80 and over, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Artery Disease, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypercholesterolemia, Injections, Subcutaneous, Cholesterol, LDL, Liver Function Tests, Male, Middle Aged, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, RNA, Small Interfering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
